Next Phase Newsletter

A venture capital fund based in the US has invested the majority of its portfolio in the Life Sciences and HealthTech sectors. The firm plans to invest in two-or-three new portfolio companies and make one or two additional follow-on investments. The firm typically makes Pre-Seed, Seed and Series A investments ranging in size from $250K to $1M, and its largest total investment (including follow-ons) in any one company is $3.25M.  
 
The firm invests primarily in the Life Sciences and HealthTech sectors and in a wide range of sub-sectors within those sectors. The firm is sector and subsector agnostic and is open to evaluating different types of technologies. 
 
The firm invests in companies with growth-minded founders with proven track records, defensible market positions, and the ability to be positive cash-flow within 12-24 months. The firm is minority-owned and is committed to managing a diverse portfolio of companies with the potential to deliver above-average returns, including companies with minority, female and SEDI founders. The firm is an active investor that can provide valuable de-risking strategic and operational guidance and support through its venture studio, which helps portfolio companies reduce the risk of costly mistakes, get to market sooner and scale faster. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Founded in 2019, a Chinese venture capital firm is specialized in the growth-stage life science investments and IT area. Currently, the firm has 300M RMB assets under management. While generally being flexible on the allocation size, the firm typically makes investments ranging from 10-60 MM RMB (~1.4-8.5 MM USD). 
 
The firm has strong interest in investing novel pharmaceuticals, including orphan drugs. Also, the firm is open to digital health, especially the ones has big data application in life science area. So far, the firm has no interest in diagnostics nor medical devices products. 
 
The firm prefers companies with a China Angle, especially the ones open to register an entity in China. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A globally diversified healthcare venture capital firm has a mission is to deliver medical solutions and savings to over 100M people around the world. The firm seeks out visionary entrepreneurs who combine integrity, intelligence, and passion to address pressing healthcare challenges innovatively and ethically. The firm’s globally diversified portfolio comprises 60% allocation in the U.S. and the remaining 40% distributed across Singapore, India, and the EU. The firm’s engagement extends beyond financial investment. The firm provides robust post-investment support, focusing on strategy development, distribution, cross-border expansion, and manufacturing/OEM partnerships. They strive to establish an ecosystem that fosters collaboration among start-ups, government bodies, clinical, investment, and commercial partners. This approach ensures that portfolio companies receive comprehensive support, aiding in their growth and impactful contribution to the healthcare sector. 
 
Focused on early to growth-stage investments, the firm specializes in sectors including medical devices, digital health, healthcare services, and AI-empowered solutions. The firm has particular interests in critical areas such as oncology, ophthalmology, brain health, orthopedics, cardiology, and other chronic diseases management. 
 
The firm does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A deep tech and medical-focused venture capital firm based in Europe typically participates in early-stage, Seed to Series A financing rounds, with check sizes averaging between 1M and 1.5M EUR. Follow-on investment is possible. The firm seeks opportunities across Europe, excluding the UK, and is flexible in both leading and co-investing. The firm can be an active investor and may seek board or observer seats on a case-by-case basis. 
 
The firm is interested in medical devices, software, manufacturing and AI/machine learning related technologies. The firm also seeks novel approaches in tech bio, such as technologies that support drug discovery, drug development, expedite clinical trials, or gather real-world data. Other areas of interest include new genomic analysis. Traditional therapeutics are not of interest. The firm prefers to engage with companies early, and could interact with companies 1–2 years before the seed stage. 
 
The firm does not have specific requirements for a company’s founding team but prefers teams with diverse gender representation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm headquartered in the US focuses on investing in early stage, typically pre-seed to Series A, across deeptech, life sciences, and the intersection between technology and healthcare in the U.S. market. The firm is backed by companies and family offices in the U.S., Europe, and Singapore, with partners that are all entrepreneurs in the life science space. The firm will usually co-invest with typical check sizes ranging from $100k-1M. The firm also partners with LPs for acquisition opportunities, and in those cases, they will do deals up to $100M but it is acquiring the company as opposed to investing. The firm plans to invest in 20 global companies per year in addition to incubating 1-2 companies a year. The firm is also willing to help companies go into emerging areas like Africa and Asia. 
 
The firm is opportunistic for life science and deeptech investments. Big focus areas for the firm include AI, health tech, neuroscience, life sciences tools, and therapeutics in the early-stage. The firm is also open to orphan diseases. In terms of therapeutics, the firm will invest in companies that are Pre-Clinical to Phase I. 
 
The firm does not have management team requirements and does not require taking a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A women-led venture capital firm is dedicated to women’s health and have invested in over 10 companies in this space. The firm is looking to invest in life science companies that address women’s health between Seed to Series A in Europe, the UK, and Israel, eventually scaling to the U.S as well. The firm is open to acting as a lead investor for smaller rounds, however they are currently co-investing especially as they start to invest in the U.S. 
 
The firm is open to any life science sector including therapeutics, diagnostics, medical devices, digital health, etc. in the clinical stage as long as the company addresses women’s health. This includes innovations that solely, disproportionately, and/or differently affect women, such as menopause, autoimmune diseases, and heart disease. The firm is open to anywhere from therapeutics and genomics to consumer products. The firm requires to see clinical data and efficacy in the technology. In terms of medical devices, the firm is open to all classes. The only exception that the firm does not invest in is pharmaceuticals. 
 
The firm does not have specific team requirements, however the firm will take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm with offices in US and China has an active investment and advisory arm. The firm invests in early-stage life science ventures, from Seed to Series B, with Series A and Series B being the firm’s sweet spot. Typical size of investment ranges from $1-2M in seed stage companies, and $3-5M in venture round companies. In addition, the firm supports entrepreneurs to expand to the Chinese market, and the firm has multiple offices in China and needed expertise to support the entrepreneur’s vision. Currently, the firm is most interested in companies based in USA, Israel, and Western Europe. 
 
The firm will consider therapeutics, medical devices, diagnostics, and life science tools. The firm is most interested in medical devices, and their interests include medtech and biotech combination products, novel methods of drug delivery, in vitro diagnostics (novel instruments and reagents), etc. The firm is interested in both 510K and PMA devices. Within therapeutics, the firm is more interested in clinical assets and typically do not look at pre-clinical companies unless the opportunity is compelling. Current main indication areas of interest for the firm are cardiovascular disease, oncology, and women’s health. 
 
The firm seeks to work with management teams who are passionate about their technology and dedicated to creating values for the larger community. Though the firm is able to support companies who are interested in entering the China market, having a China angle is not necessary for investment. The firm can act as either a lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.